DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Focal Prostate Radio-Frequency Ablation

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Procedure: Radio-Frequency Ablation (RFA)

First Posted Date: 2014-12-31

Last Posted Date: 2021-08-06

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 6

Registration Number: NCT02328807

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas

Phase 1

Completed

Conditions: Malignant Glioma

Interventions: Radiation: Hypofractionated Stereotactic Irradiation (HFSRT)
Drug: Pembrolizumab
Drug: Bevacizumab

First Posted Date: 2014-12-10

Last Posted Date: 2023-10-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 32

Registration Number: NCT02313272

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer

Phase 1

Completed

Conditions: Bladder Cancer
Carcinoma, Transitional Cell
Renal Pelvis Cancer
Ureter Cancer
Urethra Cancer

Interventions: Drug: Enzalutamide
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2014-11-25

Last Posted Date: 2019-08-01

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 10

Registration Number: NCT02300610

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, United States

Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer

Phase 1

Completed

Conditions: Hepatocellular Cancer
Liver Cancer

Interventions: Drug: Trametinib
Drug: Sorafenib

First Posted Date: 2014-11-17

Last Posted Date: 2021-06-10

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 17

Registration Number: NCT02292173

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

Phase 1

Terminated

Conditions: Gastric Cancer
Esophageal Cancer

Interventions: Drug: Selinexor
Drug: Irinotecan

First Posted Date: 2014-11-05

Last Posted Date: 2016-01-15

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 3

Registration Number: NCT02283359

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Capitalizing on a Teachable Moment to Promote Smoking Cessation

Not Applicable

Completed

Conditions: Smoking Cessation

Interventions: Behavioral: Self-Help (SHI)
Behavioral: Usual Care (UC)

First Posted Date: 2014-10-28

Last Posted Date: 2020-08-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 35

Registration Number: NCT02276664

Locations: 🇺🇸
H Lee Moffitt Cancer Center, Tampa, Florida, United States

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of Skin
Carcinoma, Squamous Cell

Interventions: Drug: Pegylated Interferon alpha-2b
Drug: Capecitabine
Drug: 5-FU

First Posted Date: 2014-08-15

Last Posted Date: 2022-10-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 8

Registration Number: NCT02218164

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence

Early Phase 1

Completed

Conditions: Smoking Cessation
Tobacco Dependence

Interventions: Drug: Varenicline
Other: Laboratory Assessments
Other: Counseling and Support Materials

First Posted Date: 2014-07-29

Last Posted Date: 2020-11-27

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 86

Registration Number: NCT02202499

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases

Phase 1

Terminated

Conditions: Brain Metastases
Brain Lesions
Generalized Malignancy, Primary

Interventions: Drug: TPI 287
Procedure: Fractionated Stereotactic Radiotherapy (FSRT)

First Posted Date: 2014-07-11

Last Posted Date: 2021-02-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 15

Registration Number: NCT02187822

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Selinexor
Drug: Liposomal doxorubicin
Drug: Dexamethasone

First Posted Date: 2014-07-10

Last Posted Date: 2023-01-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 28

Registration Number: NCT02186834

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy